ABM-1310 clinical trials
Also written ABM-1310.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses ABM-1310 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ABM-1310
- 3
Studies by the year they started
3 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
ABM Therapeutics Shanghai Company Limited (2) · ABM Therapeutics Corporation (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses ABM-1310 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid TumorsTerminatedPhase 1ABM Therapeutics Shanghai Company LimitedNCT05501912Written as ABM-1310
- A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain TumorsTerminatedPhase 1ABM Therapeutics Shanghai Company LimitedNCT05892653Written as ABM-1310
- Safety and Tolerability of ABM-1310 in Patients With Advanced Solid TumorsTerminatedPhase 1ABM Therapeutics CorporationNCT04190628Written as ABM-1310
Codes
What other systems call ABM-1310 · ClinicalTrials.gg INT018724
- UNII (FDA) ZV5W411ZUUABM-1310One source FDA
- NCI Thesaurus C170951BRAF(V600E) Kinase Inhibitor ABM-1310One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZV5W411ZUU | ABM-1310 | One source FDA |
| NCI Thesaurus | C170951 | BRAF(V600E) Kinase Inhibitor ABM-1310 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.